← All trials
NCT06515184
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Sep 13, 2024
- Primary completion
- Dec 31, 2027
- Completion date
- Dec 31, 2027
- First posted
- Jul 23, 2024
- Last posted
- Sep 20, 2024
- Enrollment
- 192
- Arms / groups
- 3 / —
- Source
- AACT · ctgov ingestion
Sponsors
- University of California, San DiegoLead sponsor
- University of California, San DiegoOfficial
- Department of DefenseCollaborator
- University of California, San DiegoSponsor investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.